Akebia Therapeutics

AKBA

Market cap $390M

CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 22,576 shares of Akebia's common stock on November 28, 2025.

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs -- WALTHAM, Mass. , Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline.

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 at 4:30 PM EST.

The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andrew Kassin - BTIG, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Vafseo® (vadadustat) Q3 2025 net product revenues grew to  $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ESAs Akebia to host Conference Call at 8:00 a.m. ET on Monday, November 10, 2025 CAMBRIDGE, Mass.

Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.